<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">UK Deputy Chief Medical Officer Professor Jonathan Van-Tam reportedly told that the vaccine developed by Oxford University and AstraZeneca could be ready for deployment in January, while Sir Jeremy Farrar, a member of the Sage Science Advisory Council and Director of the Wellcome Foundation, said that at least one of the UK vaccine portfolios could be ready by spring. Up to now, three COVID-19 vaccines have been licensed for use by several national regulatory authorities. None of the WHO EUL/PQ approvals have yet been issued, but we foresee an evaluation of the Pfizer vaccine and other candidates soon. Trials of 5 vaccine candidates for effectiveness and safety effects, including these three (and for Moderna and AstraZeneca), have been widely announced via press releases, but only one (AstraZeneca) has published findings in peer-reviewed literature. There are several new vaccine candidates currently under production for COVID-19. Once the vaccines have been proven to be safe and reliable, they must be licensed by national authorities, developed to exacting specifications and delivered. WHO is partnering with stakeholders around the world to help plan crucial measures in this process, and to promote equal access to secure and reliable COVID-19 vaccines for the billions of people who will need them (
 <xref rid="b0235" ref-type="bibr">Mahase, 2021</xref>)
</p>
